Floatz logo

6 assets in Juvenile Dermatomyositis

Therapeutic assets addressing Juvenile Dermatomyositis, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Jnj-78436735
Juvenile Dermatomyositis
National Institute of Allergy and Infectious Diseases (NIAID)P2CCC (53)
Moderna Covid-19 Vaccine Rna
Juvenile Dermatomyositis
National Institute of Allergy and Infectious Diseases (NIAID)P2CCC (53)
Monovalent [B.1.351] Cov2 Pres Dtm-As03
Juvenile Dermatomyositis
National Institute of Allergy and Infectious Diseases (NIAID)P2CCC (53)
Methotrexate
Juvenile Dermatomyositis
National Institute of Allergy and Infectious Diseases (NIAID)P2CCC (52)
Tozinameran
Juvenile Dermatomyositis
National Institute of Allergy and Infectious Diseases (NIAID)P2CCC (50)
bnt162b2
Juvenile Dermatomyositis
National Institute of Allergy and Infectious Diseases (NIAID)P2CC (43)